series-c-plus
Stage
1
Investors
About
Lyell develops next-generation CAR T-cell therapies aimed at providing one-time treatments that deliver lasting remissions for patients with cancer, including hematologic malignancies and solid tumors.
Explore Lyell's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.